Treatment outcomes of gestational choriocarcinoma before and after EMA/CO introduction in Mongolia: a 15-year retrospective cohort study
By
Ulziijargal Sukhbat
Gandolgor Batsuuri
Eiko Yamamoto
Terkhen Turbat
Oyujin Ulziibaatar
Baatarkhuu Oidov
Ita Daryanti Saragih
Namuun Ganzul
Yen-Liang Liu
Jargalsaikhan Badarch
July 17, 2026
Clinical Scorecard: Outcomes of Gestational Choriocarcinoma Treatment in Mongolia: A 15-Year Retrospective Analysis Before and After the Introduction of EMA/CO Therapy
At a Glance
Category Detail
Condition Gestational Choriocarcinoma Key Mechanisms Etoposide–methotrexate–actinomycin D/cyclophosphamide–vincristine (EMA/CO) chemotherapy Target Population Women diagnosed with gestational choriocarcinoma in Mongolia Care Setting Oncology treatment centers in Mongolia
Key Highlights
Higher complete remission rates observed post-EMA/CO implementation (97.0% vs 69.7%) Significant decrease in disease-related mortality after EMA/CO introduction (3.0% vs 30.3%) Vaginal bleeding was the most common presenting symptom (84.8%) 54.5% of patients presented with metastatic disease (FIGO stage III–IV) The lungs were the most frequent site of metastasis Guideline-Based Recommendations
Diagnosis
Routine serum β-hCG surveillance for early detection Accurate staging using WHO and FIGO scoring systems Management
Standardized multi-agent chemotherapy regimens Additional interventions such as surgery and radiotherapy when indicated Monitoring & Follow-up
Serial measurement of β-hCG for treatment monitoring and detection of recurrence Risks
Metastatic disease remains a key determinant of prognosis Patient & Prescribing Data
Post-implementation of EMA/CO therapy showed improved outcomes in terms of remission and mortality.
Clinical Best Practices
Timely referral to specialized oncology centers Enhanced healthcare infrastructure for early pregnancy monitoring Standardized management protocols for gestational choriocarcinoma Related Resources & Content
